OncLive TV

R. Lor Randall, MD, FACS, discusses global consensus on managing periprosthetic joint infections in sarcoma and complex bone reconstructions.

Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.

Jessica Donington, MD, MSCR, discusses how the availability of targeted therapy has affected surgical decision-making in early-stage lung cancer.

C. Ola Landgren, MD, PhD, discusses evolving risk-stratification strategies in honor of Multiple Myeloma Awareness Month.

Sandip M. Prasad, MD, discusses future directions for investigating mitomycin intravesical solution in the ENVISION trial for NMIBC.

Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

Jorge Cortes, MD, discusses the variety of long-term patient goals in chronic myeloid leukemia and how prioritizing them leads to different TKI selections.

Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

Sandip M. Prasad, MD, details key findings from a post hoc analysis of CR rates and DOR in the phase 3 ENVISION trial.

During CRC Awareness Month, John L. Marshall, MD discusses whether the biology and origin of EO-CRC fundamentally differ from that of late-onset disease.

Sandip M. Prasad, MD, discusses prior data from the phase 3 ENVISION trial in NMIBC.

Marla D. Lipsyc-Sharf, MD, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

David R. Wise, MD, PhD, discusses the safety profile of pasritamig plus docetaxel in patients with mCRPC.

Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormonal therapy decision-making in patients with early-stage, HR-positive breast cancer.

Multiple experts weigh in on the potential of MRD as a primary end point following recently issued FDA draft guidance for the end point in myeloma.

In honor of SCAC Awareness Day, Richard Kim, MD, discusses the shift toward personalized therapy and introduction of retifanlimab into the SCAC arsenal.

David R. Wise, MD, PhD, discusses the efficacy of pasritamig plus docetaxel in patients with mCRPC.

Rita Nanda, MD, discusses important research that has been conducted by the Translational Breast Cancer Research Consortium.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss which future advances being examined in clinical trials in gynecologic oncology are catching their eyes.

David R. Wise, MD, PhD, unpacks the design of a phase 1b trial of pasritamig plus docetaxel in mCRPC.

Emese Zsiros, MD, PhD, FACOG, discusses the FDA approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer.

Rita Nanda, MD, discusses the I-SPY 2 study in patients with breast cancer.

R. Lor Randall, MD, FACS, discusses the clinical utility and global variability of DAIR procedures for periprosthetic joint infection in sarcoma.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the most interesting recent trends in clinical trials in gynecologic oncology.

Wendy Stock, MD, discusses recommendations from the ASH Guidelines on utilizing pediatric-inspired regimens in adolescent/young adult ALL.

Colin Vale, MD, discusses long-term efficacy data for blinatumomab and ponatinib in Ph+ B-ALL and significance of achieving remission without procedures.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss their approaches to supporting patients with gynecologic malignancies during clinical trials.

Rita Nanda, MD, discusses the importance of clinical trials in breast cancer.

Nicole Lamanna, MD, discusses the FDA approval of first-line acalabrutinib plus venetoclax for CLL and the phase 3 AMPLIFY trial data that supported it.

Marwan G. Fakih, MD, discusses the shift in SCAC management after the approval of retifanlimab and the resulting need for better second-line strategies.